Study of Platelet Population Changes Under Circulatory Support With ECMO (ECMO-POP)

December 30, 2025 updated by: University Hospital, Strasbourg, France
Advances in flow cytometry techniques have led to a better understanding of platelet phenotypes and have revealed the existence of four major platelet populations with distinct functional properties (native, proaggregating, procoagulating, or apoptotic). These phenotypes have a significant impact on the hemostatic capacity of blood platelets, and a proportional change in these populations during ECMO treatment could, at least in part, contribute to the observed complications.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

75

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Strasbourg, France, 67091
        • Recruiting
        • Service d'anesthésie-réanimation - CHU de Strasbourg - France
        • Contact:
        • Principal Investigator:
          • Charles TACQUARD, MD, PhD
        • Sub-Investigator:
          • Marie MULLER, MD
        • Sub-Investigator:
          • Thomas RESCHWEIN, MD
        • Sub-Investigator:
          • Walid OULEHRI, MD
        • Sub-Investigator:
          • Laurent Sattler, MD
        • Sub-Investigator:
          • Béatrice HECHLER, Statistician

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

- Adult patient (≥18 years) treated in one of the intensive care units of the Anesthesia and Intensive Care Department at Strasbourg University Hospital and implanted with veno-arterial or veno-venous ECMO within the previous 24 hours.

Description

Inclusion Criteria:

  • Adult patient (≥18 years) treated in one of the intensive care units of the Anesthesia and Intensive Care Department at Strasbourg University Hospital.
  • Implanted with veno-arterial or veno-venous ECMO within the previous 24 hours.

Exclusion Criteria:

  • Subject who has expressed their opposition to participating in the study.
  • Subject under legal protection.
  • Subject under guardianship or curatorship.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic)
Time Frame: Days 1, 3, and 7 after the initiation of ECMO treatment.
Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic) on Days 1, 3, and 7 after the initiation of ECMO treatment.
Days 1, 3, and 7 after the initiation of ECMO treatment.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 11, 2025

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

March 11, 2027

Study Registration Dates

First Submitted

December 30, 2025

First Submitted That Met QC Criteria

December 30, 2025

First Posted (Estimated)

January 12, 2026

Study Record Updates

Last Update Posted (Estimated)

January 12, 2026

Last Update Submitted That Met QC Criteria

December 30, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 9614

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Respiratory Failure

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe